Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rae

Showing results (221-230 of 292) with videos related to

Pageof 30
Sort By:
Journal of Developmental Origins of Health and Disease|May 17, 2018
Influence of maternal adiposity, preterm birth and birth weight centiles on early childhood obesity in an Indigenous Australian pregnancy-through-to-early-childhood cohort studyK G Pringle, Y Q Lee, L Weatherall, et al.
Investigational New Drugs|November 6, 2018
Pazopanib with low fat meal (PALM) in advanced renal cell carcinomaMelissa A Reimers, Maryann M Shango, Stephanie Daignault-Newton, et al.
Oncotarget|February 2, 2017
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancerMartina S J McDermott, Alexander A Chumanevich, Chang-Uk Lim, et al.
Pharmacogenomics|July 24, 2020
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathyYongzhen Chen, Fang Fang, Kelley M Kidwell, et al.
The Pharmacogenomics Journal|August 24, 2016
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerD L Hertz, K M Kidwell, N J Seewald, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 2022
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptomsDaniel L Hertz, Julie A Douglas, Robert M Miller, et al.
The Pharmacogenomics Journal|May 8, 2009
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsJ M Rae, M J Sikora, N L Henry, et al.
Breast Cancer Research and Treatment|January 21, 2009
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohortN Lynn Henry, James M Rae, Lang Li, et al.
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Pageof 30

Showing results (221-230 of 292) with videos related to

Sort By:
Pageof 30
Journal of Developmental Origins of Health and Disease|May 17, 2018
Influence of maternal adiposity, preterm birth and birth weight centiles on early childhood obesity in an Indigenous Australian pregnancy-through-to-early-childhood cohort studyK G Pringle, Y Q Lee, L Weatherall, et al.
Investigational New Drugs|November 6, 2018
Pazopanib with low fat meal (PALM) in advanced renal cell carcinomaMelissa A Reimers, Maryann M Shango, Stephanie Daignault-Newton, et al.
Oncotarget|February 2, 2017
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancerMartina S J McDermott, Alexander A Chumanevich, Chang-Uk Lim, et al.
Pharmacogenomics|July 24, 2020
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathyYongzhen Chen, Fang Fang, Kelley M Kidwell, et al.
The Pharmacogenomics Journal|August 24, 2016
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerD L Hertz, K M Kidwell, N J Seewald, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 2022
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptomsDaniel L Hertz, Julie A Douglas, Robert M Miller, et al.
The Pharmacogenomics Journal|May 8, 2009
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsJ M Rae, M J Sikora, N L Henry, et al.
Breast Cancer Research and Treatment|January 21, 2009
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohortN Lynn Henry, James M Rae, Lang Li, et al.
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Pageof 30